Voclosporin
Focal Segmental Glomerulosclerosis (FSGS)
Key Facts
About aurinia-pharmaceuticals
Aurinia Pharmaceuticals is a Canadian biotech company with a mission to deliver transformative therapies for autoimmune diseases. Its core achievement is the successful FDA approval and commercialization of LUPKYNIS, a first-in-class oral treatment for lupus nephritis. The company's strategy is to maximize the global potential of LUPKYNIS while leveraging its expertise to develop a pipeline of novel candidates, including a dual BAFF/APRIL inhibitor, to build a sustainable, multi-product autoimmune franchise.
View full company profileAbout aurinia-pharmaceuticals
Aurinia Pharmaceuticals is a Canadian biotech company with a mission to deliver transformative therapies for autoimmune diseases. Its core achievement is the successful FDA approval and commercialization of LUPKYNIS, a first-in-class oral treatment for lupus nephritis. The company's strategy is to maximize the global potential of LUPKYNIS while leveraging its expertise to develop a pipeline of novel candidates, including a dual BAFF/APRIL inhibitor, to build a sustainable, multi-product autoimmune franchise.
View full company profileTherapeutic Areas
Other Focal Segmental Glomerulosclerosis (FSGS) Drugs
| Drug | Company | Phase |
|---|---|---|
| KRP-205 | kissei-pharmaceutical | Phase II |
| DMX-200 | amicus-therapeutics | Phase 3 |
| Sparsentan | travere-therapeutics | Phase 3 |